Back to top
more

Poseida Therapeutics (PSTX)

(Real Time Quote from BATS)

$2.94 USD

2.94
366,785

+0.16 (5.76%)

Updated Nov 7, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.

Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label

by Zacks Equity Research

The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.

Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Poseida Therapeutics, Inc. (PSTX) Could Surge 277%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to a 281% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

New Strong Sell Stocks for August 27th

by Zacks Equity Research

CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021